119 related articles for article (PubMed ID: 9109050)
1. Control of poorly soluble drug dissolution in conditions simulating the gastrointestinal tract flow. 2. Cocompression of drugs with buffers.
Chakrabarti S; Southard MZ
J Pharm Sci; 1997 Apr; 86(4):465-9. PubMed ID: 9109050
[TBL] [Abstract][Full Text] [Related]
2. Control of poorly soluble drug dissolution in conditions simulating the gastrointestinal tract flow. 1. Effect of tablet geometry in buffered medium.
Chakrabarti S; Southard MZ
J Pharm Sci; 1996 Mar; 85(3):313-9. PubMed ID: 8699336
[TBL] [Abstract][Full Text] [Related]
3. Hierarchical Mass Transfer Analysis of Drug Particle Dissolution, Highlighting the Hydrodynamics, pH, Particle Size, and Buffer Effects for the Dissolution of Ionizable and Nonionizable Drugs in a Compendial Dissolution Vessel.
Salehi N; Al-Gousous J; Mudie DM; Amidon GL; Ziff RM; Amidon GE
Mol Pharm; 2020 Oct; 17(10):3870-3884. PubMed ID: 32886520
[TBL] [Abstract][Full Text] [Related]
4. Effect of PEG 4000 on the dissolution rate of naproxen.
Vélaz I; Sánchez M; Martín C; Martínez-Ohárriz MC
Eur J Drug Metab Pharmacokinet; 1998; 23(2):103-8. PubMed ID: 9725465
[TBL] [Abstract][Full Text] [Related]
5. Controlled release of acidic drugs in compendial and physiological hydrogen carbonate buffer from polymer blend-coated oral solid dosage forms.
Wulff R; Rappen GM; Koziolek M; Garbacz G; Leopold CS
Eur J Pharm Sci; 2015 Sep; 77():246-53. PubMed ID: 26093053
[TBL] [Abstract][Full Text] [Related]
6. Establishing virtual bioequivalence and clinically relevant specifications using in vitro biorelevant dissolution testing and physiologically-based population pharmacokinetic modeling. case example: Naproxen.
Loisios-Konstantinidis I; Cristofoletti R; Fotaki N; Turner DB; Dressman J
Eur J Pharm Sci; 2020 Feb; 143():105170. PubMed ID: 31783158
[TBL] [Abstract][Full Text] [Related]
7. Solution-mediated phase transformation of salts during dissolution: investigation using haloperidol as a model drug.
Greco K; Mcnamara DP; Bogner R
J Pharm Sci; 2011 Jul; 100(7):2755-68. PubMed ID: 21328581
[TBL] [Abstract][Full Text] [Related]
8. Understanding improved dissolution of indomethacin through the use of cohesive poorly water-soluble aluminium hydroxide: effects of concentration and particle size distribution.
Tay T; Allahham A; Morton DA; Stewart PJ
J Pharm Sci; 2011 Oct; 100(10):4269-80. PubMed ID: 21560127
[TBL] [Abstract][Full Text] [Related]
9. A dynamic system for the simulation of fasting luminal pH-gradients using hydrogen carbonate buffers for dissolution testing of ionisable compounds.
Garbacz G; Kołodziej B; Koziolek M; Weitschies W; Klein S
Eur J Pharm Sci; 2014 Jan; 51():224-31. PubMed ID: 24095865
[TBL] [Abstract][Full Text] [Related]
10. Low Buffer Capacity and Alternating Motility along the Human Gastrointestinal Tract: Implications for in Vivo Dissolution and Absorption of Ionizable Drugs.
Hens B; Tsume Y; Bermejo M; Paixao P; Koenigsknecht MJ; Baker JR; Hasler WL; Lionberger R; Fan J; Dickens J; Shedden K; Wen B; Wysocki J; Loebenberg R; Lee A; Frances A; Amidon G; Yu A; Benninghoff G; Salehi N; Talattof A; Sun D; Amidon GL
Mol Pharm; 2017 Dec; 14(12):4281-4294. PubMed ID: 28737409
[TBL] [Abstract][Full Text] [Related]
11. A novel approach for predicting the dissolution profiles of pharmaceutical tablets.
Paus R; Hart E; Ji Y
Eur J Pharm Biopharm; 2015 Oct; 96():53-64. PubMed ID: 26170163
[TBL] [Abstract][Full Text] [Related]
12. Coamorphous drug systems: enhanced physical stability and dissolution rate of indomethacin and naproxen.
Löbmann K; Laitinen R; Grohganz H; Gordon KC; Strachan C; Rades T
Mol Pharm; 2011 Oct; 8(5):1919-28. PubMed ID: 21815614
[TBL] [Abstract][Full Text] [Related]
13. Novel lipid-based formulations enhancing the in vitro dissolution and permeability characteristics of a poorly water-soluble model drug, piroxicam.
Prabhu S; Ortega M; Ma C
Int J Pharm; 2005 Sep; 301(1-2):209-16. PubMed ID: 16046087
[TBL] [Abstract][Full Text] [Related]
14. Effects of particle morphology, pore size and surface coating of mesoporous silica on Naproxen dissolution rate enhancement.
Guo Z; Liu XM; Ma L; Li J; Zhang H; Gao YP; Yuan Y
Colloids Surf B Biointerfaces; 2013 Jan; 101():228-35. PubMed ID: 23010024
[TBL] [Abstract][Full Text] [Related]
15. Dissolution of a Biopharmaceutics Classification System Class II Free Acid from Immediate Release Tablets Containing a Microenvironmental pH Modulator: Comparison of a Biorelevant Bicarbonate Buffering System with Phosphate Buffers.
Haznar-Garbacz D; Hoc D; Garbacz G; Lachman M; Słomińska D; Romański M
AAPS PharmSciTech; 2022 Jul; 23(6):203. PubMed ID: 35882674
[TBL] [Abstract][Full Text] [Related]
16. Influence of the physiological variability of fasted gastric pH and tablet retention time on the variability of in vitro dissolution and simulated plasma profiles.
Kovačič NN; Pišlar M; Ilić I; Mrhar A; Bogataj M
Int J Pharm; 2014 Oct; 473(1-2):552-9. PubMed ID: 25064726
[TBL] [Abstract][Full Text] [Related]
17. Dissolution and permeation properties of naproxen from solid-state systems with chitosan.
Corti G; Maestrelli F; Cirri M; Mura P; Zerrouk N
Drug Deliv; 2008 Jun; 15(5):303-12. PubMed ID: 18763161
[TBL] [Abstract][Full Text] [Related]
18. Soluble filler as a dissolution profile modulator for slightly soluble drugs in matrix tablets.
Dvorácková K; Rabisková M; Masteiková R; Muselík J; Krejcová K
Drug Dev Ind Pharm; 2009 Aug; 35(8):930-40. PubMed ID: 19274510
[TBL] [Abstract][Full Text] [Related]
19. Dissolution properties of co-amorphous drug-amino acid formulations in buffer and biorelevant media.
Heikkinen AT; DeClerck L; Löbmann K; Grohganz H; Rades T; Laitinen R
Pharmazie; 2015 Jul; 70(7):452-7. PubMed ID: 26373205
[TBL] [Abstract][Full Text] [Related]
20. Influence of chitosan and its glutamate and hydrochloride salts on naproxen dissolution rate and permeation across Caco-2 cells.
Maestrelli F; Zerrouk N; Chemtob C; Mura P
Int J Pharm; 2004 Mar; 271(1-2):257-67. PubMed ID: 15129993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
